Votrient (pazopanib) for Gastrointenstinal Stromal Tumors (GIST)
Pazopanib(Votrient) is a new drug that is approved for kidney cancer and acts in ways that may be effective in GIST. These are important pathways for GIST tumors and several trials are avaluating this drug in GIST, including: Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST), NCT Number: NCT01323400, Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST) NCT Number: NCT01391611 and Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib NCT Number: NCT01524848. There is also the PAZOPANIB IN ADVANCED GASTROINTESTINAL STROMAL TUMORS REFRACTORY TO IMATINIB AND SUNITINIB: A Non-comparative Phase II Multicenter Study by the Scandinavian Sarcoma Group.
Several studies showed activity in other sarcomas, and the FDA approved it for soft tissue sarcomas in April of 2012, but thus far there has not been a supportive study in GIST and currently there are no guidelines that support this drug for GIST.
For Professional version see here